Prostatitis classification as well as treatment decisions are primarily based on differentiation of the inflammatory status in prostate-specific material. At the same time, methods used for detection of inflammation are semi-quantitative and not finally standardized. The main aim of this study was to suggest more precise methods for detection of prostate inflammatory status. Additional aims were to define optimal cut-off points of various tests in order to discriminate between inflammatory and non-inflammatory condition and to analyze the prevalence of inflammatory prostatitis in the groups of symptomatic prostatitis, lower urinary tract symptoms and control subjects. This prospective study included 541 patients (with prostatitis symptoms, with lower urinary tract symptoms and controls) at Tartu University Hospital, Estonia. Leukocyte counts in first-void urine, expressed prostatic secretion and post-massage urine as well as interleukin-6 in prostate secretion specimens were determined. Based on ROC curve analysis, we detected potential normal values for leukocytes in expressed prostatic secretion (<0.5 M/mL), leukocytes in post-massage urine (<4 WBCs per HPF) and IL-6 in prostatic secretion (<50 nmol/mL). Using these newly defined normal values, we detected inflammatory reaction in prostate-specific materials in 24.3%, 53.4% and 69% in control, lower urinary tract symptoms and prostatitis group, respectively. Limitation: only subjects with prostatic fluid volume >0.04 mL were included. We propose standardized method for analysis of inflammatory reaction in prostate-specific materials. Based on these newly defined normal values, we verified high prevalence of inflammatory forms of disease in both study groups, but also high prevalence of asymptomatic inflammatory prostatitis among control group of Estonian men. Combining results of analysis of the different inflammatory markers from available prostatespecific materials allows us to differentiate better between inflammatory and non-inflammatory forms of prostate diseases and hence to choose more precise treatment strategies.
INTRODUCTION
Prostatitis is a widespread condition in men of all ages with an estimated prevalence of 2-16%, whereas in Nordic areas the figures tend to be in the higher end (Krieger et al., 2008) . It has been estimated that prostatitis may affect up to 50% of men at some point in their lives (McNaughton Collins & Barry, 1998) . Studies in infertile patients (Wolff, 1995) , unselected young men (Korrovits et al., 2008) , and prostate biopsies (Nickel et al., 2007) indicate that a substantial number of prostatitis cases may progress asymptomatically.
Despite extensive research during recent years, chronic prostatitis (CP) is still poorly characterized and neither etiology nor pathogenesis of the disease is clear. Although a prostatic secretion test for diagnosing the bacterial component in prostatitis was described already in 1930 (Nickel, 1930) , it was only in 1968 that the more sophisticated 4-glass test was introduced for the same purpose (Meares & Stamey, 1968) . Later, Nickel (1997) modified the original Meares and Stamey test into a more userfriendly 2-glass test. All these tests are primarily focused on the bacterial component of prostatitis. Much less effort has been put into improving methods of detection of inflammatory status of the prostate (secretion). At the same time, we know that clear microbial cause revealed by routine cultures may be identified only in 5-10% of prostatitis cases (McNaughton et al., 2007) and a new classification of prostatitis (National Institutes of Health Summary Statement, 1995) is principally based on differentiation of the non-inflammatory/inflammatory status of the prostate-specific material. The same classification also accepts semen as a prostate-specific material. The limit of significant leukocytospermia is defined as over one million white blood cells (WBC) per mL of semen in WHO guidelines (World Health Organization, 1999) , but reference values or even diagnostic thresholds for the diagnosis of inflammation in prostate-specific materials such as expressed prostate secretion (EPS) and postmassage (Post-M) urine are still missing (Muller et al., 2001) . Most commonly, leukocytosis in EPS is defined as >5 or >10 WBCs per high-power field (HPF) (Meares & Stamey, 1968) . All methods used in clinical practice for detection of inflammatory activity are semi-quantitative and lack reproducibility and accuracy (Muller et al., 2001) . Use of various critical numbers of leukocytes in different studies leave their findings incomparable. These values are also limited due to the lack of available data on prostate-specific variables in control groups compared to welldefined groups with various prostate diseases.
There is increasing evidence for the role of cytokines as inflammatory mediators in chronic prostatitis. Several studies have indicated that pro-inflammatory cytokines are associated with seminal leukocytes (Eggert-Kruse et al., 2001; Kopa et al., 2005) and may therefore serve as additional inflammatory markers in the diagnostic work-up. IL-6 is a cytokine that plays a key role in the acute phase of inflammation but also dictates the transition from acute to chronic inflammation (Gabay, 2006) . Elevated serum IL-6 levels have been associated with morbidity and disease activity in a variety of chronic diseases (Gabay, 2006) , but has also proved as a good marker of inflammatory prostatitis in semen (Korrovits et al., 2006) . Although the diagnostic usage of IL-6 in prostate-specific materials has not been standardized, there are several studies (Hochreiter et al., 2000; Nadler et al., 2000; Paulis et al., 2003; Liu et al., 2009 ) that indicate a good correlation of various cytokines with neutrophils in prostate-specific material.
The main aim of this study was to suggest more precise methods for detection of prostate inflammatory status by comparing different prostate-specific materials. The second aim was to define optimal cut-off points of various tests to discriminate between inflammatory and non-inflammatory condition in groups of men with various prostate diseases but also in the control group. The third aim was to analyze the prevalence of inflammatory prostatitis in the groups of symptomatic prostatitis, LUTS, and control subjects.
MATERIALS AND METHODS

Subjects
The original study group was recruited prospectively at the Andrology Center, Tartu University Hospital, over the period of 28 months (January 1, 2007 -April 26, 2009 ) and consisted of 870 men. Inclusion criteria for symptomatic patients were symptom history for at least 3 previous months and exclusion criteria for the whole group were stated according to the suggestions of the NIH workshop on chronic prostatitis in Bethesda, MD, USA, 1995 (National Institutes of Health Summary Statement, 1995 . None of these men had received antimicrobial therapy within 3 months and anti-inflammatory medications for at least 1 month before evaluations. Control group consisted of symptom-free men who requested prophylactic control of their prostate health.
Only those subjects where sufficient amount (over 0.04 mL) of prostate secretion (EPS) could be obtained by prostatic massage were enrolled into current analysis. In the majority of cases, WBC count in pre-massage (Pre-M) urine was 0 or 1 per HPF. We also included four subjects who presented with 4-20 WBCs in Pre-M, but the WBCs number in their Post-M was at least five times higher. All subjects with signs suggestive to urethritis and/ or balanoposthitis were excluded from the study. The final number of study subjects was 541.
Subjects whose NIH-CPSI pain score was higher than 8 and those with pain score between 4-7, but positive for two questions most specific for prostatitis (perineal and ejaculatory pain/ discomfort), were included into the prostatitis group (n = 242, mean age 45 years, range 22 to 75) irrespective of their IPSS score. Subjects not classified as prostatitis patients but with some degree of voiding problems (IPSS score ≥1) were defined as lower urinary tract symptoms (LUTS) group (n = 163, mean age 58, range 36-71). LUTS patients were further subdivided according to IPSS scores as following: 1-7, mild; 8-19, moderate; 20-35, severe. Control group (n = 136, mean age 50, range 20-75) did have neither pain nor voiding symptoms.
Material collection
Subjects were told to abstain from ejaculation for at least 4 days. Before material collection, subjects were asked to wash their hands and glans penis with soap and water. Thereafter, subjects were told to collect approximately 30-40 mL of firstvoid urine (Pre-M) representing the urethral washout but also bladder urine. Prostatic secretion (EPS) was obtained by digital massage no later than 5 min after voiding and collected into sterile polypropylene containers. After the digital massage, subjects were told to collect the first 20 mL of urine (Post-M). As it turned out, it was difficult for the subjects to control the amount of Post-M urine and therefore real amount collected ranged from 15 to 40 mL.
Expressed prostatic secretion processing
Processing of EPS started within 20 min after collection. EPS analysis was performed in the same way as recommended according to WHO guidelines for semen analysis (World Health Organization, 1999) .
EPS volume was estimated by weighing the collection tube with the sample and subsequently subtracting the predetermined weight of the empty tube assuming 1 g = 1 mL. Appearance of the EPS was recorded.
Round cell count
A wet mount was made by placing 10 lL of well-mixed EPS onto a glass slide. A 22 mm covered glass was used. Examination with phase-contrast optics at 4009 magnification of wet preparation began as soon as the 'flow' in the preparation had ceased. All round cells were recorded in at least five fields of view (FOV). The wet preparation was used to estimate the approximate concentration (four round cells per FOV approximately correspond to the concentration of 1 million per mL) and to select the most appropriate dilution for the haemocytometer analysis. Standard dilutions were 1+4 and 1+1. The exact volume of fluid was withdrawn from the well-mixed EPS sample with a positive displacement pipette and added to the diluent in a test tube with a tight lid.
Tubes containing the diluted sample were mixed for at least 10 sec (on a vortex mixer) immediately before filling the counting chamber. After mixing, an aliquot of about 6-10 lL was taken with a pipette to one side of an improved Neubauer haemocytometer. Then a second aliquot was placed on the other side. Filled chamber was let to rest for 10-15 min in a humid box to allow the round cells to sediment to the grid of the counting chamber. All round cells were counted in the whole 25-square central grid in both sides of the chamber. If the difference between the two counts was equal to or <10% average, the cell counts were corrected for dilution factor. If not, the counts were discarded and new assessments started from dilution were made.
Cytological analysis and neutrophil counts in EPS
Smears were made from the wet mount slides (using 10 lL of EPS). Smears were air-dried, Bryan-Leishman stained and examined using an oil-immersion microscope by experienced andrology lab technicians. Percentage of WBC from all round cells was counted. Whenever possible, 100 round cells were counted twice and the mean value was registered.
Neutrophil concentration (millions per mL) was calculated using the known concentration of round cells multiplied by neutrophil percentage from the cytological analysis and divided by 100.
Two technicians processed EPS samples during the course of this study.
Detection of interleukin-6
Interleukin-6 levels in prostatic secretion plasma were measured using the Immulite automated chemiluminescence immunoassay analyzer (Immulite DPC, Los Angeles, CA, USA) according to manufacturer's instructions. If the secretion volume was <20 lL, a known volume of prostatic secretion plasma was diluted according to manufacturer's instructions. Any dilution factor was recorded and results were corrected accordingly.
Detection of inflammation in fractionated urine
Both Pre-M and Post-M urine were sent for analysis. Modified Steinheimer supravital staining was used to ease identification of leukocytes. A quantity of 10 mL of urine was centrifuged for 10 min at 200 g. The supernatant was poured off and 50 lL of Reastine urine stain (Reagena, Toivala, Finland) was added to the remaining pellet (0.5 mL). Then 13 lL of stained sediment was transferred to a microscopic slide and covered with a cover glass of 18 9 18. During examination with phase contrast optics at 4009 magnification, round cells in at least 10 FOV were recorded and average number calculated.
Methods of quality control
In the initial phase of the study, replication analysis was made both for IL-6 and neutrophil count. Four replicate analyses were performed for 10 prostatic secretion samples. The microscopic method showed a mean coefficient of variation in 12%, while for IL-6 the same result was 14%.
Internal quality control scheme was implemented. The basic aspect of quality control was to duplicate the assessments of a sufficient number of cells (at least 200 cells whenever possible) with verification that the duplicates do not differ too much. In addition, each week at least one replicate assessment of the round cell counts and cytological analysis by both participating technologists was organized.
Statistical methods
Statistical analyses were performed using SPSS 17.0 (IBM, Chicago, IL, USA) for WINDOWS (Microsoft, Redmond, WA, USA).
The coefficient of variation for different methods determined by replicates was compared using the Mann-Whitney test. Between-group differences were calculated with Kruskal-Wallis test, the differing group or groups were isolated using a multiple comparison procedure (Dunn's method). Pearson correlation analysis was used for assessing correlation between groups.
Receiver operating characteristic (ROC) curve analysis was used for optimal cut-off points of various markers of inflammation and for sensitivity and specificity testing.
Ethical considerations
Participation in the study was voluntary. Written informed consent was obtained from all study subjects. The study has been approved by the Ethics Review Committee on Human Research of the University of Tartu, Estonia (permission No. 166/T-14).
RESULTS
Results of neutrophil counts and IL-6 levels in prostatic secretion as well as leukocyte counts in Post-M urine in each study group are summarized in Table 1 . Significant differences between the study groups were revealed in all the observed parameters. When all groups were analyzed together, good correlations were found between all parameters of inflammatory reaction investigated: Post-M urine WBCs vs. EPS WBCs (r = 0.556); Post-M urine WBCs vs. EPS IL-6 (r = 0.531) and EPS WBCs vs. EPS IL-6 (r = 0.697). All correlations were statistically significant at the p < 0.001 level.
In the next phase of the study, we focused on detecting the optimal cut-off points of WBC counts in two prostate-specific materials (EPS and Post-M urine) and IL-6 levels in EPS. First, we tested optimal cut-off point of WBC counts in Post-M urine with various levels (0.2 to 1.0 M/mL) of WBCs in EPS and found that the previously (Muller et al., 2001) proposed limit of 0.5 M/ mL of WBCs in EPS gives the best predictive ability with area under the curve 0.840 in our study group, as well. The model based on this (but also other tested EPS WBC counts) cut-off point predicts an optimal limit of 4 WBCs per HPF in Post-M urine (sensitivity 80% and specificity 79%).
Next, based on limit of equal or more than four WBCs per HPF in Post-M urine, we tested for sensitivity and specificity of various cut-off points for WBCs and IL-6 level in EPS. The results for the whole study group are presented in Table 2 . We found that the optimal balance between sensitivity and specificity was achieved at the IL-6 level of 30-50 nmol/L and at the neutrophil level of 0.3 to 0.5 M/mL. Although there are some indications to set up various cut-off points for different study groups, we decided to use common thresholds. Weighting superior higher specificity, the cut-off points of 50 nmol/mL for EPS IL-6 and 0.5 M/mL for EPS WBCs were chosen for future analyses.
In the final phase of the study, we analyzed how the detected cut-off points may affect clinical diagnosis of prostatitis. Of the 541 men investigated, 244 (45.1%) had an elevated number of leukocytes in either their EPS or Post-M urine. Of these 244 men, 133 (24.6%) had elevated number of leukocytes in both prostate specific materials, 63 (11.6%) only in Post-M urine and 48 (8.9%) only in EPS. Elevated IL-6 levels together with normal leukocyte counts in both investigated materials were present in 43 (7.9%) cases.
Prevalence of inflammatory prostatitis based on defined cutoff levels in the control group, LUTS patients and prostatitis patients are presented in Table 3 . We found that inflammatory reaction measured as an elevated number of leukocytes in Post-M urine and/or prostatic secretion was detectable in 19.1% of controls. The same figure was 39.9% and 63.2% among LUTS and prostatitis patients, respectively. Adding elevated values of EPS IL-6 into this estimation increased the prevalence of inflammatory cases to 24.3% in control group, 53.4% in LUTS group and 69.0% in prostatitis group.
There was no correlation (r < 0.1 in all cases) between any tested marker of inflammation and IPSS scores in LUTS patients or with NIH-CPSI pain domain in prostatitis patients.
DISCUSSION
In our study, we propose a standardized method for analysis of prostate-specific materials (EPS and Post-M urine), as well as potential normal values for WBCs and IL-6 in prostatic secretion and WBCs in Post-M urine. We found an optimal balance between specificity and sensitivity at the level of 0.5 M/mL of neutrophils in EPS, four leukocytes per field of view in Post-M urine sediment and EPS IL-6 levels at 50 nmol/L.
Precise detection of inflammation is important both for diagnostic purposes and treatment of prostatitis. Widespread clinical practice but also the consensus statement from 1998 (Bjerklund Johansen et al., 1998) recommends that all patients with chronic prostatitis, i.e. both culture-positive and culturenegative, should receive antibiotic therapy; justification for this being that failure to isolate a bacterium does not necessarily mean that one is not present and there is a reasonable possibility that a good clinical response can be achieved. Our previous study (Punab et al., 2003) , based on semen, indicated that elevated leukocyte levels are associated with quantitative microbiological parameters -increased number of various bacterial species, but also with elevated total bacterial counts present.
Previous studies have shown that a pro-inflammatory cytokine IL-6 shows significantly higher seminal plasma values in patients with leukocytospermia than in those without (Eggert-Kruse et al., 2001; Kopa et al., 2005) , which was also confirmed by our previous study (Korrovits et al., 2008) . IL-6 is an important mediator of inflammatory processes and a marker of silent genital inflammations in seminal plasma (Eggert-Kruse et al., 2001) where the prostate appears to be its main source (Matalliotakis WBC, white blood cell; EPS, expressed prostatic secretion; IL-6, interleukin-6; Post-M, post-massage; HPF, high-power field; SD, standard deviation; LUTS, lower urinary tract symptoms. 1-3 Kruskal-Wallis test;
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Dunn's test. , 1998) . Therefore, detection of IL-6 can be suggested as an additional diagnostic tool for men with prostate diseases to rule out possible inflammatory factor, as well as for men with asymptomatic leukocytospermia to gain additional data regarding the activity of inflammation. In our present study, prostatic secretion IL-6 showed good correlation with the rest of inflammatory markers used. Being automated and therefore potentially free of subjective errors, IL-6 may serve as a valuable additional tool in the correct diagnostic work-up of men with suspected prostate diseases. We found that up to 69% of symptomatic prostatitis patients harbored inflammatory forms of prostatitis. Inflammatory reaction was also detectable in 53.4% of LUTS patients and in 24.3% of the controls. The latter subgroup can be diagnosed as having asymptomatic inflammatory (NIH IV) prostatitis. So far, there are only a few published studies that have determined signs of asymptomatic inflammation based on prostate-specific material: expressed prostatic secretions (Carver et al., 2003; Nickel et al., 2003; Wu et al., 2013) , post-massage urine (Potts, 2000; Nickel et al., 2003) or histological specimens from prostate (Shimomura et al., 2003) . In these studies, prevalence of asymptomatic inflammatory prostatitis ranged from 11 to 42%. Also, several studies on chronic symptomatic prostatitis have determined WBC counts in prostate-specific materials (EPS, Post-M urine, semen) of their control subjects (Christiansen et al., 1991; Nickel et al., 2003) , thus actually including men with NIH IV category prostatitis, too. Nickel et al. (2003) found that men with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) had statistically higher leukocyte counts in all segmented urine samples and EPS compared to asymptomatic control men. However, the control population also had a high (20%) prevalence of leukocytes in any prostate-specific material. Christiansen et al. (1991) found that 15% of their asymptomatic controls had significant leukocytospermia. Nickel (2008) recently stated that inflammation of the prostate gland appears to be more closely related to benign prostatic hyperplasia (BPH) than to a clinical syndrome of chronic prostatitis. Our study does not support this opinion entirely, as prevalence of an inflammatory reaction in prostate-specific materials was clearly higher in prostatitis than LUTS subjects of our study group. However, when comparing groups with various severity of LUTS, a gradual increase in severity of the inflammatory reaction in groups with more severe LUTS can be observed. Discrimination between LUTS accompanying chronic prostatitis and 'simple' LUTS usually because of BPH warrants further studies in the view of possible new treatment strategies.
It is intriguing that inflammatory reaction in Post-M urine does not always coincide with elevated leukocyte numbers in prostate secretion. One possible cause of this discrepancy can be various degrees of occlusion of glandular ducts. Histologically, prostate duct occlusions often have been shown to be associated with focal acute and chronic inflammation and with corpora amylaceae (De Marzo et al., 2007) . This occlusion may significantly affect the natural but also forced 'clearance' of the prostate ducts during diagnostic manipulation/prostate massage. Therefore, it seems important to always look for inflammatory reaction in both EPS and post-massage urine.
Important finding of our study is that there is no correlation between values of any investigated markers of prostate inflammation and symptom scores of prostate diseases. This is in concordance with data presented by Nickel et al. (2003) . Future studies are needed to elucidate the origin of prostatic complaints and aside from biological markers, more attention should be paid to the neurological, cognitive and emotional factors behind prostatitis symptoms in the future (T€ urk & Kullisaar, 2011) .
The major limitation of our study was associated with standardization of analysis of prostate-specific materials. One option to improve the test quality is to weigh Post-M sample volume, which in our subjects fluctuated between 15-40 mL. This adds us the possibility to calculate the dilution factor before determining the leukocyte count in Post-M urine. Still, even in this case we cannot get 100% reproducible figures, as we are not able to fully standardize the massage process itself and reaction of the prostate during manipulation. Another possible limitation of this study is the fact that we included only subjects where an EPS volume over 0.04 mL could be obtained. Therefore, we cannot extend our conclusions about prevalence of inflammatory forms of diseases to the whole group of subjects.
Also, the age range of our study subjects was relatively wide, thus probably including subjects with prostatic hyperplasia in older subjects, as well. However, it may not have been avoided because of the prospective study design with expected heterogeneity of the study population.
CONCLUSIONS
Based on clinical material of 541 men, we propose a standardized method for analysis of prostate-specific materials (EPS and Post-M urine) as well as potential normal values for markers of inflammation, WBCs, and IL-6 in these specimens. Based on these newly defined normal values, we verified a high prevalence of inflammatory forms of disease both in the groups of prostatitis and LUTS patients, but also a relatively high prevalence of asymptomatic inflammatory prostatitis (NIH group IV) among the control group of Estonian men. Detection of IL-6 in prostatic secretion can serve as an additional diagnostic tool for men with prostate diseases to rule out possible inflammatory factor. Combining results of analysis of the different inflammatory markers from available prostate-specific materials allows us to better differentiate between inflammatory and non-inflammatory forms of prostate diseases and hence to choose more precise treatment strategies.
